select trial semaglutide Trial: reduces the risk of MACE by 20% in people with overweight or obesity, pre-existing CVD, and no diabetes. Average weight loss of -9.4% at 51 months SELECT Cardiovascular Trial Information |

Unfortunately, some people find that they sweat more than necessary, which can cause lifestyle disruption

I dont know if its placebo from knowing whats in the powder or if its actually working, but I definitely feel like this helps with my triathlon training sessions, adds Amanda

Fry was double excited because the GLP-1 drug not only helped curb his appetite but also his alcohol consumption

2020 Feb;1461(1):104-126

Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently unlicensed by the MHRA or EMA and still being evaluated in Phase 2 and Phase 3 clinical trials